A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.
暂无分享,去创建一个
X. Montalban | J. Río | M. Prinz | M. Comabella | R. Martin | L. Nonell | F. Deisenhammer | M. Camiña-Tato | M. Fernandez | E. Caballero | E. Julià | C. López | A. Sánchez | J. Lünemann | M. Tórtola
[1] M. Krumbholz,et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. , 2008, Brain : a journal of neurology.
[2] B. Becher,et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. , 2008, Immunity.
[3] Pablo Villoslada,et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. , 2008, Archives of neurology.
[4] À. Rovira,et al. Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients , 2008, Multiple sclerosis.
[5] G. Lemke,et al. TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response , 2007, Cell.
[6] R. Steinman,et al. Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program , 2007, The Journal of Experimental Medicine.
[7] A. Minagar,et al. Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study , 2007, Journal of Neuroinflammation.
[8] R. Steinman,et al. Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program , 2007, The Journal of experimental medicine.
[9] E. Coccia,et al. Sensitization to TLR7 Agonist in IFN-β-Preactivated Dendritic Cells1 , 2007, The Journal of Immunology.
[10] S. Miller,et al. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ TH-17 cells in relapsing EAE , 2007, Nature Immunology.
[11] C. Wijbrandts,et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients , 2007, Annals of the rheumatic diseases.
[12] P. Gregersen,et al. An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity , 2007, Molecular medicine.
[13] E. Coccia,et al. Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. , 2007, Journal of immunology.
[14] A. Lutterotti,et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients , 2006, Multiple sclerosis.
[15] G. Freeman,et al. Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response1 , 2006, The Journal of Immunology.
[16] C L Verweij,et al. A subtype of multiple sclerosis defined by an activated immune defense program , 2006, Genes and Immunity.
[17] E. Coccia,et al. Differential responsiveness to IFN‐α and IFN‐β of human mature DC through modulation of IFNAR expression , 2006 .
[18] Xiaodong Zhou,et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. , 2006, Rheumatology.
[19] C. Lucchesi,et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[20] X. Montalban,et al. Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.
[21] E. Coccia,et al. Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. , 2006, Journal of leukocyte biology.
[22] M. Panelius,et al. Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS , 2005, Journal of Neuroimmunology.
[23] P. Park,et al. Discovering statistically significant pathways in expression profiling studies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] T. Speed,et al. Colon cancer prognosis prediction by gene expression profiling , 2005, Oncogene.
[25] L. Semendric,et al. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector , 2005, Hepatology.
[26] B. Becher,et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis , 2005, Nature Medicine.
[27] L. Greller,et al. Transcription-Based Prediction of Response to IFNβ Using Supervised Computational Methods , 2004, PLoS biology.
[28] M. Peterson,et al. Coordinate overexpression of interferon‐α–induced genes in systemic lupus erythematosus , 2004 .
[29] F. Watzinger,et al. Real-Time Quantitative PCR Assays for Detection andMonitoring of Pathogenic Human Viruses in ImmunosuppressedPediatricPatients , 2004, Journal of Clinical Microbiology.
[30] S. Hanash,et al. Global and Distinct Targets of IRF-5 and IRF-7 during Innate Response to Viral Infection* , 2004, Journal of Biological Chemistry.
[31] G. Lesinski,et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. , 2004, Journal of the National Cancer Institute.
[32] E. Coccia,et al. Viral infection and Toll‐like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte‐derived dendritic cells , 2004, European journal of immunology.
[33] M. Peterson,et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. , 2004, Arthritis and rheumatism.
[34] P. Fisher,et al. Expression regulation and genomic organization of human polynucleotide phosphorylase, hPNPase(old-35), a Type I interferon inducible early response gene. , 2003, Gene.
[35] T. Stewart. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. , 2003, Cytokine & growth factor reviews.
[36] C. Bao,et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray , 2003, Genes and Immunity.
[37] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[38] Carlos Nos,et al. Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.
[39] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[40] N. Kadowaki,et al. Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.
[41] F. Belardelli,et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. , 2001, Immunity.
[42] Weir,et al. Low Levels of Interferon‐α Induce CD86 (B7.2) Expression and Accelerates Dendritic Cell Maturation from Human Peripheral Blood Mononuclear Cells , 1999, Scandinavian journal of immunology.
[43] B. Williams,et al. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .
[44] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[45] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[46] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[47] C. Heusser,et al. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells , 1993, The Journal of experimental medicine.
[48] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[49] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .